Medical Resources reshapes management

Article

Imaging services chain Medical Resources has made a number of moves to strengthen its management team. The company named Lawrence Ramaekers to its previously vacant post of CEO and has also begun a review of its related-party transactions in response to

Imaging services chain Medical Resources has made a number of moves to strengthen its management team. The company named Lawrence Ramaekers to its previously vacant post of CEO and has also begun a review of its related-party transactions in response to concerns from shareholders and members of senior management.

Ramaekers, who will serve as acting CEO, is a principal at management consulting firm Jay Alix & Associates and specializes in interim management assignments. He has previously worked as CEO at national restaurant chain Family Restaurants, and as COO of National Car Rental.

The investigation of the company's related-party transactions will focus principally on fees for investment banking, advisory, and other services paid to 712 Advisory Services, an affiliate of Medical Resources chairman Gary Siegler. In addition to assessing the manner by which the company considers related-party transactions, the review will examine the fairness of all such transactions and the adequacy of their disclosure. The review will also develop recommendations on what changes, if any, should be made to the company's procedures.

In the quarter ended September 30, 712 Advisory Services received around $1 million for services rendered involving six different acquisitions with an aggregate transaction value of approximately $33 million, according to Medical Resources. All earlier payments to 712 have previously been reported on a timely basis, according to the firm. Siegler and 712 believe that all of its financial advisory fees are and were proper, but will nevertheless abide by the findings of the independent review, according to the company.

Medical Resources has retained outside counsel to investigate the 712 transactions. A committee of directors formed by the board will initially oversee the review, although two new directors who will soon be added to the board will assume ultimate responsibility for the review.

Recent Videos
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Related Content
© 2025 MJH Life Sciences

All rights reserved.